For over two decades, the Fischetti laboratory has pioneered the use of phage lysins and related antibacterial enzymes — collectively called “enzybiotics” — as effective alternatives to traditional antibiotics to stop the rising global incidence of antimicrobial resistant life-threatening bacterial infections.
In a newly established partnership, the Fischetti Lab is collaborating with the Brady lab to leverage their soil metagenomic library, applying an innovative discovery workflow based on an algorithm developed by Edmondo Campisi, the project’s principal investigator. This algorithm is designed to sift through the genetic richness of the soil and identify previously unknown lysin molecules produced by uncommon bacteria and their viruses (phages). Through this partnership, the Fischetti and Brady Labs aim to accelerate the development of groundbreaking therapeutics against resistant bacterial pathogens
